Navigation Links
ISTO Technologies, Inc. Appoints Blake Miles as Vice President of Sales
Date:11/13/2007

ST. LOUIS, Nov. 13 /PRNewswire/ -- ISTO Technologies, Inc. a privately held orthobiologics company, today announced the appointment of Blake Miles as Vice President of Sales.

ISTO President and CEO Mitchell Seyedin said, "We are pleased to attract a proven talent from the medical device industry, with an impressive knowledge of orthobiologic products." Prior to joining ISTO, Blake was a Regional Sales Manager with a distributorship for Depuy Spine, Inc. a global designer, manufacturer, and supplier of spinal devices and a subsidiary of Johnson & Johnson. Mr. Miles has 14 years of sales and marketing experience. His tenure in medical sales included successful senior level sales positions with Medtronic Sofamor Danek, Ansell Healthcare, Kos Pharmaceutical, and Physician Sales & Service. "Throughout his career, Blake has shown leadership and an entrepreneurial spirit in managing successful sales teams in the orthopedic field," said Seyedin. Mr. Miles will organize and drive a sales distributor network to launch ISTO's first commercial product, InQu, a bone graft extender and substitute.

InQu represents a new class of synthetic biomaterial scaffold designed to optimize structural and biological properties to support bone cell growth. InQu is a biopolymer composite of hyaluronic acid which is entangled within the three-dimensional backbone created by synthetic polyester. Hyaluronic acid, a ubiquitous component of natural tissue, is known to play a predominant role in tissue morphogenesis, cell migration, adhesion, and cell differentiation.

In addition to its biomaterial platform technology, ISTO is also developing cartilage regeneration products centered on its patented cell-based technology. Cartilage regeneration is often called the "holy grail" of the orthopedic industry because of its potential to restore function to damaged joints that otherwise have limited healing potential. Cartilage serves as a "shock absorber" protecting all joints, including spinal discs, from the wear and tear experienced during motion. ISTO's first cartilage product is currently in clinical trials.

About ISTO

ISTO Technologies, Inc. is an orthobiologics company focused on developing differentiated products for sports medicine, spinal therapy, and trauma. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at http://www.istotech.com or contact the company at 314-995-6049.


'/>"/>
SOURCE ISTO Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
2. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
3. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
4. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
5. ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products
6. ReBuilder Medical Technologies, Inc. Reports Monthly Sales in 2007 Nearly Doubling Monthly Sales in 2006, Including Record Daily Sales in September 2007
7. ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device; Expects Sales to Increase 30%
8. ReBuilder Medical Technologies, Inc. Announces Agreement with Internet Marketer Helio Health; Anticipates 12% Additional Profit
9. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
10. ReBuilder Medical Technologies, Inc. Increases Manufacturing Space to Meet Demand
11. ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ARI Network Services, Inc. (NASDAQ: ARIS) ... eligible dealer websites for its network of more than 650 U.S.-based dealers. Rhino, a ... equipment including rotary and flail mowers and cutters, rear blades, post hole diggers, pasture ...
(Date:3/29/2017)... NY (PRWEB) , ... March 29, 2017 , ... ... men’s and women’s professional squash, announced it has enlisted New York City-based sports ... The agency will develop and procure sponsorship opportunities for the Professional Squash Association ...
(Date:3/29/2017)... ... ... main cause of hay fever in the United States, with an estimated 95 percent of ... July each year; with the worst time for sufferers being June and July. , ... provide an effective defense against grass pollen; they are proven in independent studies to trap ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered ... feedback from high school and college students who have participated in the program every ... and YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to ...
(Date:3/29/2017)... ... 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale ... for the remaining days of March, the price will be only $19.97. The EXOUS ... of just $10 (regular retail price $19.97). , The special promotional prices are to ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  The leader in accelerated ... Drs. Sam Daher , Manal Ibrahim , ... David Couchat will be the featured microlecture presenters at ... American Association of Orthodontists (AAO) Annual Session, April 21-25, ... the microlectures beginning daily at 11:20 a.m. On the ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, a ... GSP 301, an investigational fixed-dose combination of mometasone ... administered twice-daily as a nasal spray being studied ... results are from a recently completed Phase 3 ... 301 combination therapy versus mometasone, olopatadine or placebo. ...
(Date:3/29/2017)... 29, 2017 Transparency Market ... provides an exhaustive study of the U.S. substance abuse ... companies are functional in this market at present, ... leading companies, such as GlaxoSmithKline Plc., Pfizer Inc., ... on various marketing strategies to increase their visibility, ...
Breaking Medicine Technology: